A multiscale graph embedding workflow prioritized LC-61, which the study experimentally evaluated against L. infantum. The finding is a specific in-vitro compound result; it does not establish clinical efficacy, safety or a validated target.
Technology: Multiscale-aware graph embedding and machine learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article/PubMed and institutional manuscript identify LC-61 and its experimental parasite assay.
- Still unknown: Exact prior structures and broader dose/replication details remain open.
- AI role: Graph embedding ranks candidate molecules for assay; human selection and experimental testing follow.
Evidence sources: https://doi.org/10.1021/acs.jcim.5c02947
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: author-institution primary full-text PDF; PubMed primary metadata. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Random-forest prediction and chemical filters helped narrow commercial compounds for experimental testing. Of 17 selected compounds, the paper reports 11 with inhibitory activity against Candida albicans at tested concentrations. Compound 17 had an IC50 of 0.071 μM and MIC of 4.5 μM, compared with fluconazole values of 0.39 μM and 0.78 μM, respectively; its lower IC50 but higher MIC does not establish superiority. The reported selectivity-index definition appears inconsistent with tabulated values, so this draft omits that index. Cell assays do not establish clinical efficacy or safety.
Technology: Random-forest classifiers and regressors; chemical similarity filtering
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary full text reports 17 experimentally tested compounds and 11 active; compound-specific IC50/MIC values are stated with different fluconazole comparators.
- Still unknown: Molecule-level previous activity, exact compound identities and independent replication remain to review.
- AI role: Random-forest models predict activity and toxicity to prioritize commercially available compounds; selected compounds are experimentally tested.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12320878/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary full-text article on PMC indexed text and methods/results read; online date, title and DOI verified..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning workflow guided virtual screening for parasite N-myristoyltransferase, followed by testing of selected compounds in parasite assays. The primary preprint reports a bounded set of measured antimalarial candidates, including LabMol-394, while target assignment remains computational. This is not clinical efficacy or proof of target engagement.
Technology: Selective-bias virtual screening; machine-learning target/activity models
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Primary preprint full text reports tested selected candidates and parasite activity.
- Still unknown: Exact earliest journal version and compound prior art remain open; target-specific binding is not experimentally established.
- AI role: Model-based selective-bias workflow scores target/activity candidates for experimental testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10925453/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary preprint full text; PubMed primary record/abstract and affiliations. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An AI-assisted virtual-screening cascade using shape-based and machine-learning models prioritized potential Plasmodium kinase inhibitors. Eight virtual hits were experimentally evaluated; LabMol-167 inhibited P. berghei ookinete conversion and P. falciparum blood-stage parasites at nanomolar concentrations and showed low cytotoxicity in mammalian cells. A possible additional PK5 target was proposed from computational target fishing and docking, not demonstrated experimentally. This is a preclinical hit result and does not establish therapeutic efficacy. The article appeared online on 2021-03-16.
Technology: AI-assisted virtual screening combining shape-based and machine-learning models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Eight virtual hits were evaluated; LabMol-167 showed nanomolar activity in P. berghei ookinete conversion and P. falciparum blood-stage assays, with low mammalian-cell cytotoxicity.
- Still unknown: The PK5 dual-target mechanism is proposed from computational target fishing and docking; in-vivo efficacy and clinical benefit are not established.
- AI role: Shape-based and machine-learning virtual screening prioritized candidates for experimental evaluation; the abstract explicitly links the integrated AI-assisted screen to this candidate-identification workflow.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/33247522/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PubMed abstract, publication metadata, and author-affiliation block; claim limited to the findings explicitly stated in the abstract..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.